Should mutational analyses of tumor samples bypass histopathology?

Journal of Thoracic Oncology

Volumn 2, Issue 5, 2007, Pages 375-376

  Tsao, Ming Sound ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; FORMALDEHYDE; K RAS PROTEIN; MUTANT PROTEIN; PARAFFIN; PROTEIN P53; TUMOR MARKER;

DISEASE CLASSIFICATION; DNA DETERMINATION; EDITORIAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; HISTOLOGY; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MUTATIONAL ANALYSIS; NEEDLE BIOPSY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TISSUE FIXATION; TUMOR; BIOPSY; DIAGNOSIS, MEASUREMENT AND ANALYSIS; GENETICS; LUNG TUMOR; NOTE; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROGNOSIS;

BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION PROFILING; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; LUNG NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 34249861605     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01.JTO.0000268668.64625.f2     Document Type: Editorial

References (10)

1. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. New Engl J Med 2006;355:570-580.
2. Chen H-Y, Yu S-L, Chen C-H, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. New Engl J Med 2007;356:11-20.
3. Sequist LV, Joshi VA, Jänne PA, et al. Epidermal growth factor receptor mutation testing in the care of lung cancer patients. Clin Cancer Res 2006;12(14 Suppl):4403s-4408s.
4. Bunn PA, Dziadziuszko R, Varella-Garcia M, et al. Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy. Clin Cancer Res 2006;12:3652-3656.
5. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:1-14.
6. Tsao M-S, Sakurada A, Cutz J-C, et al. Molecular and clinical predictors of response and prognostic markers of survival in patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group Trial BR. 21. New Engl J Med 2005;353:133-144.
7. Hirsch FR, Varella-Garcia M, Bunn PA et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small cell lung cancer. J Clin Oncol 2006;24:5034-5042.
8. Lim EH, Zhang S-L, Yu K, et al. An alternative approach to determining therapeutic choices in advanced non-small cell lung carcinoma (NSCLC): maximizing the diagnostic procedure and the use of low-volume lung biopsies. J Thorac Oncol 2007;2: XX-XX.
9. Sakurada A, Shepherd FA, Tsao M-S. EGFR tyrosine kinase inhibitors in lung cancer: impact of primary and secondary mutations. Clin Lung Cancer 2006;7(Suppl 4):S138-S144.
10. Jänne PA, Borras AM, Kuang Y, et al. A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res 2006;12:751-758.